AlphAIAlphAI — Financial news for AI agents
investing.comOCT 302 min read$FTRE

Truist raises Fortrea stock price target to $29 on margin outlook

Truist Securities raised its price target on Fortrea (NASDAQ:FTRE) to $29 from $26, maintaining a Buy rating. The stock trades at $23.14 with a $2.23B market cap. Fortrea reported a TTM book-to-bill ratio of 1.12x, below expectations, and expects Q4 adjusted EBITDA of $50M with a 7.5% margin, down from Q3. The company cited fewer working days and investments for the decline, but noted six consecutive quarters of margin upside and improving biotech demand.

Original reporting
investing.com
Published Oct 30, 2026, 8:53 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 8:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$FTRE
Bullish
medium confidence
Mentioned
$FTRE
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$FTREBullishMed
01

Why it matters

The price‑target increase reflects confidence in margin recovery despite recent earnings shortfall.

02

Market read

Analyst upgrade may drive short‑term buying pressure in FTRE and influence peer biotech stocks.

03

What to watch

Potential downside from sequential revenue slowdown and weaker book‑to‑bill ratio.

Relevance 7/10Novelty 6/10Timing: pre-market today

Background

Fortrea reported mixed Q3 results and a lower-than-expected book‑to‑bill ratio, prompting analyst reassessment.

Company-level read

Ticker impact

$FTREBullishMedium confidence
Context

Truist Securities raised Fortrea's price target to $29 from $26.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

The new target reflects improved margin outlook and EBITDA expectations, prompting buying interest.

Market effects

Sector

Boosts sentiment for the biotech services sector.

Regional

May lift US biotech stocks in early trading.

Global

Limited to US-listed biotech investors.

Counterpoint

What could challenge this read

Some investors may view the target raise as premature given recent earnings miss.

Key entities

  • company
    Fortrea Holdings Inc.

    Biotech services provider

  • analyst_firm
    Truist Securities

    Research arm that raised the price target

Read at source← All news

Related articles

OCT 30
$FTREMed

Fortrea Holdings Inc (FTRE) (Q3 2026) Earnings Call Highlights: Backlog Cleanup

Fortrea Holdings (FTRE) reported a $558M backlog adjustment, not impacting near-term revenue. Q4 EBITDA guidance was lowered due to fewer working days and IT investment. Gross margins improved from portfolio mix and efficiencies. CEO Anshul Thakral and CFO Jason Knobloch discussed growth strategies, including acquisitions like Worldwide Clinical Trials, and market recovery trends in biotech and biopharma. The company aims for mid-teens EBITDA margins and sees increasing RFP activity.

finance.yahoo.com2 min
OCT 29
$FTREHighAI 8/10

Fortrea (FTRE) Q3 2026 Earnings Call Transcript

Fortrea (FTRE) reported Q3 2026 revenue of $691.5M, adjusted EBITDA of $58M, and a book-to-bill ratio of 1.12x. The company raised full-year guidance and completed an acquisition to expand its clinical pharmacology capacity. Fortrea's strategy focuses on revenue growth and margin expansion through commercial, operational, and financial excellence.

finance.yahoo.com3 min
OCT 29
$FTREHighAI 8/10

What Fortrea (FTRE) Said on Its Q3 Earnings Call

Fortrea (FTRE) reported Q3 net income of $0.6M, up from a loss of $15.9M YoY. Adjusted net income was $27.9M, and adjusted EPS was $0.28. Operating cash flow improved to $60.8M. The company acquired Early Phase Services, expanding its clinical pharmacology network. Fortrea raised its 2026 revenue guidance to $2.665B-$2.690B and adjusted EBITDA to $210M-$218M. Management expects biotech and biopharma demand recovery.

finance.yahoo.com2 min
OCT 29
$FTREHighAI 8/10

Fortrea Q3 2026 slides: EBITDA rises 14% as revenue falls short

Fortrea Holdings (FTRE) reported Q3 2026 revenue of $691.5M, down 1.4% YoY, missing estimates by $200.83M. Adjusted EBITDA rose 14.4% to $58.0M, with margins expanding to 8.4%. EPS missed by 55.6%, and the stock fell 11% premarket. Management raised full-year guidance but warned of Q4 revenue decline. The company acquired Worldwide Clinical Trials’ Early Phase Services for $45M, improving cash flow and liquidity.

investing.com3 min
OCT 29
$FTREHighAI 8/10

Fortrea (NASDAQ:FTRE) surprises with strong Q3 2026

Fortrea reported Q3 2026 revenue of $691.5 million, beating estimates by 3.1%, with adjusted EPS of $0.28, a 28.9% beat. Adjusted EBITDA was $58 million, an 7.7% beat. The company raised its full-year revenue guidance to $2.68 billion but lowered EBITDA guidance to $214 million. Operating margin improved to 2.2%, while free cash flow margin declined to 7.6%.

finance.yahoo.com2 min